TREE NEWS update: Novo Nordisk China said it fully supports and will cooperate with Chinese authorities in cracking down on the illegal resale of medical-insurance-reimbursed drugs, following reports of diverted semaglutide. The company said patient safety comes first and urged patients to obtain the drug by prescription through legitimate channels and to follow medical guidance. The statement did not disclose the volume of affected products or identify any specific parties under investigation.
Novo Nordisk China Backs Crackdown on Illegal Ozempic Resale Drugs
AI take
The notable element is the reimbursement angle: diverted semaglutide implies leakage from insurance-covered supply, a compliance risk that touches payers and pharmacies as much as the manufacturer. Novo's public alignment with Chinese authorities reads as reputational and regulatory positioning, especially since no volumes or parties were named. How the investigation unfolds, and whether scrutiny extends to the distribution chain, is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
8m ago
China Says Malaysia PM Anwar’s Visit Reflects Close Bilateral Ties
9m ago
China Says AI Should Be Open, Inclusive and Beneficial for All
11m ago
China FM Reiterates Opposition to Unauthorized Unilateral Sanctions on Iran
11m ago
China Says It Wants to Enrich ‘Constructive Strategic Stability’ With US Ahead of Xi Visit
19m ago
Canada Weighs LNG Export Cooperation With France
29m ago
Shanghai and Shenzhen Combined Turnover Hits 2.14 Trillion Yuan